DalCor Pharmaceuticals Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $6.96M

  • Investors
  • 5

DalCor Pharmaceuticals General Information

Description

Developer of medicinal drugs intended to facilitate the efficient treatment of cardiovascular diseases. The company focuses on the development of dalcetrapib, a therapeutic targeting patients with a specific genotype to reduce fatal and non-fatal myocardial infarction, enabling healthcare providers to offer personalized treatment options for post-acute coronary syndrome patients.

Contact Information

Formerly Known As
Helium Miracle 154
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2001 Boulevard Robert Bourassa
  • Suite 1700
  • Montreal, Quebec H3A 2A6
  • Canada
+1 (514)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • 2001 Boulevard Robert Bourassa
  • Suite 1700
  • Montreal, Quebec H3A 2A6
  • Canada
+1 (514)

DalCor Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DalCor Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 28-Aug-2026 $6.96M Completed Clinical Trials - Phase 3
5. Secondary Transaction - Private 01-May-2026 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series D) 13-Sep-2023 Completed Clinical Trials - Phase 3
3. Later Stage VC 14-Sep-2020 Completed Clinical Trials - Phase 3
2. Early Stage VC (Series B) 13-May-2016 $123M $173M Completed Clinical Trials - Phase 3
1. Early Stage VC (Series A) 01-Jan-2015 $50M $50M Completed Startup
To view DalCor Pharmaceuticals’s complete valuation and funding history, request access »

DalCor Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
B Preferred
A Preferred
To view DalCor Pharmaceuticals’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

DalCor Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of medicinal drugs intended to facilitate the efficient treatment of cardiovascular diseases. The company focu
Drug Discovery
Montreal, Canada
7 As of 2023

West Jordan, UT
 

Burlington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DalCor Pharmaceuticals Competitors (86)

One of DalCor Pharmaceuticals’s 86 competitors is InCarda Therapeutics, a Venture Capital-Backed company based in West Jordan, UT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
InCarda Therapeutics Venture Capital-Backed West Jordan, UT
Cardurion Venture Capital-Backed Burlington, MA
Renova Therapeutics Venture Capital-Backed Carlsbad, CA
Aronora Venture Capital-Backed Portland, OR
Amylyx Pharmaceuticals Formerly VC-backed Cambridge, MA
You’re viewing 5 of 86 competitors. Get the full list »

DalCor Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DalCor Pharmaceuticals Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Andes Growth Family Office Minority
Fonds de Developpement Économique Venture Capital Minority
TB Pharma Venture Capital Minority
CTI Life Sciences Fund Venture Capital Minority
Fonds de solidarite FTQ PE/Buyout Minority
To view DalCor Pharmaceuticals’s complete investors history, request access »

DalCor Pharmaceuticals FAQs

  • When was DalCor Pharmaceuticals founded?

    DalCor Pharmaceuticals was founded in 2015.

  • Where is DalCor Pharmaceuticals headquartered?

    DalCor Pharmaceuticals is headquartered in Montreal, Canada.

  • What is the size of DalCor Pharmaceuticals?

    DalCor Pharmaceuticals has 7 total employees.

  • What industry is DalCor Pharmaceuticals in?

    DalCor Pharmaceuticals’s primary industry is Drug Discovery.

  • Is DalCor Pharmaceuticals a private or public company?

    DalCor Pharmaceuticals is a Private company.

  • What is DalCor Pharmaceuticals’s current revenue?

    The current revenue for DalCor Pharmaceuticals is .

  • How much funding has DalCor Pharmaceuticals raised over time?

    DalCor Pharmaceuticals has raised $315M.

  • Who are DalCor Pharmaceuticals’s investors?

    Andes Growth, Fonds de Developpement Économique, TB Pharma, CTI Life Sciences Fund, and Fonds de solidarite FTQ have invested in DalCor Pharmaceuticals.

  • Who are DalCor Pharmaceuticals’s competitors?

    InCarda Therapeutics, Cardurion, Renova Therapeutics, Aronora, and Amylyx Pharmaceuticals are some of the 86 competitors of DalCor Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process